The drug is a mixture of two antibodies, manufactured versions of proteins that are typically produced as part of an immune response to a virus, according to Bloomberg.
Regeneron plans to study the drug in humans for the first time in June.
Other drugmakers are also developing antibody drugs for COVID-19, including Eli Lilly, AstraZeneca and Vir Biotechnology.
Read the full article here.
More articles on pharmacy:
FDA clarifies relaxed compounding rules for pharmacies
Gilead gets FDA emergency use authorization for remdesivir
AmerisourceBergen offers to buy Walgreens’ drug wholesaling division
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
